In this regard, enrichment of genes for GBM and Her2 breast cancer signaling in the whole tumor transcriptome in our studies and those from the HepG2 cell line are striking, because aberrant EGFR signaling, and to a lesser extent, Wnt-β-catenin signaling is implicated in both of these tumors. The gene discussed is EGFR; the disease is breast carcinoma.